If you have been told you need a knee replacement

A referral letter for total knee replacement is, for many patients, the moment the search for an alternative begins in earnest. Kellgren-Lawrence Grade III and IV is the range at which joint surfaces are substantially degraded and replacement is most commonly recommended — and it is precisely this cohort that ChondroFiller injection is now being evaluated to support as a joint-preservation pathway before that decision is finalised.

ChondroFiller is a CE-marked injectable collagen scaffold delivered as an outpatient, ultrasound-guided procedure. There is no theatre admission, no incision, and no surgical wound to recover from. The scaffold gels in place on the articular surface within minutes and initiates a months-long repair process drawing on the patient's own progenitor cells.

What this section cannot do — and what no scan grade alone can do — is confirm suitability in advance. KL III and IV covers a wide range of joint states. Whether a knee at this grade is a realistic candidate for ChondroFiller depends less on the number itself and more on the specific pattern of cartilage loss the imaging reveals.

How ChondroFiller works differently on heavily worn cartilage

Traditional cartilage repair techniques depend on a surgically prepared defect cavity — the repair material fills a cleaned, contained hole of limited surface area. ChondroFiller works in the opposite direction: the collagen scaffold self-gels top-down, draping and adhering across degraded articular surfaces without any requirement for a prepared cavity beneath it. This geometry is what extends the approach to diffuse joint wear. Where earlier repair methods were constrained by defect size, top-down gelation means a single injection can conform to and coat wide areas of worn surface — covering the multi-zone loss that characterises KL Grade III and IV disease, rather than targeting a single contained lesion.

The process through which the scaffold acts is acellular matrix-induced chondrogenesis. The scaffold carries no cells itself; over the six to twelve months after injection, it draws the patient's own progenitor cells from the synovium and from the subchondral bone into its structure, where those cells begin to lay down new cartilage matrix.

Two commonly compared treatments work through entirely different routes. Hyaluronic acid viscosupplementation acts as a temporary lubricant; it provides no structural repair and does not attempt to restore tissue. Polyacrylamide hydrogel (PAAG) integrates into the synovial lining as a permanent mechanical cushion — also non-regenerative, and operating on a different anatomical structure altogether. ChondroFiller is the regenerative scaffold component: it is attempting to rebuild the articular surface from within its own matrix, not supplement or pad around it.

The suitability threshold: what separates 'advanced' from 'truly end-stage'

Kellgren-Lawrence Grade IV covers a spectrum of joint states, and the clinically important boundary for ChondroFiller sits within that spectrum rather than at it.

Where a KL IV knee retains discrete or semi-discrete defects — areas of full-thickness loss surrounded by cartilage that is thinned but still present — the scaffold has viable tissue to anchor to and to recruit from. Published clinical perspective from Dr Sophie Harris at MSK Doctors identifies preserved joint space as one of the clearest predictors of ChondroFiller response; improvements in VAS pain and WOMAC function scores in published series are most consistent in patients at KL grades I to III, where residual tissue remains. The London Cartilage Clinic frames KL III–IV as an evaluation cohort for ChondroFiller — not because the grade alone confers suitability, but because within that range, sufficient residual articular tissue is often still demonstrable on MRI to support scaffold integration.

The fully end-stage picture operates under different biology. Where loss has become entirely diffuse — surrounding cartilage largely absent, bone surface in direct contact throughout — there is no residual matrix for the scaffold to anchor to, and no viable local tissue from which progenitor cells can migrate into it. In that scenario, ChondroFiller is generally ineffective. Arthrosamid, which integrates into the synovial lining and does not depend on residual articular cartilage, or total knee replacement then becomes the appropriate recommendation.

The structural heuristic clinicians apply is therefore this: MRI distinguishes a focal-within-diffuse pattern — identifiable lesion zones with intact surrounding borders — from fully generalised surface loss. Two knees carrying the same radiographic grade can present entirely differently on MRI, and it is that difference which determines whether the scaffold pathway remains viable. Patients who are genuinely end-stage by this structural measure are not ChondroFiller candidates; those who retain enough residual tissue for integration may be, even within the upper KL grades.

What the evidence currently shows

The evidence base for ChondroFiller in knee indications currently rests on case series and early prospective data rather than large randomised trials. Published outcome anchors include IKDC scores improving by approximately 30 points — on a 0–100 scale where higher values reflect better knee function and scores above 65 are broadly considered indicative of good function — and MOCART cartilage-quality scores in the range of 70–87 (out of 100), which reflect substantial structural integration of the scaffold on MRI assessment. The reported adverse-event rate of approximately 0.06% reflects a well-established safety profile across published series.

What is absent matters as much as what is present. A 2019 systematic review by Nicholls et al., published in Advances in Therapy, identified a structural gap affecting all injectable knee therapies: patients with end-stage KL Grade IV disease are routinely excluded from intra-articular injection trials. This exclusion distorts the available data — the cohort most likely to consider ChondroFiller as an alternative to replacement is precisely the cohort least represented in published evidence. No head-to-head randomised controlled trial comparing ChondroFiller with total knee replacement in KL III–IV patients has been identified; the non-surgical versus surgical question remains unanswered by controlled trial evidence.

To illustrate what a more mature injectable evidence base at this grade looks like: Arthrosamid has published registry cohorts following KL II–IV patients over two to three years, with larger patient numbers. That body of data does not transfer to ChondroFiller's mechanism or outcomes — the products operate through distinct routes on different anatomical structures — but it demonstrates that robust injectable OA evidence at advanced grades is achievable, and that ChondroFiller's data set continues to develop. For KL III–IV patients, these gaps are precisely why specialist MRI assessment, rather than radiographic grade alone, remains the appropriate basis for any candidacy decision.

When ChondroFiller is combined with other injectable therapies

At the most challenging end of the KL III–IV spectrum, a single injectable product may not address every source of pain and deterioration simultaneously. Advanced osteoarthritis at this stage typically involves both articular surface loss and synovial-space changes — two anatomically distinct problems that coexist in the same joint.

Because ChondroFiller and Arthrosamid act on different structures within the joint, delivering both in a single outpatient session allows two separate mechanisms to work in parallel rather than in sequence. This is not two doses of the same treatment; each product has a defined role in a protocol designed specifically for advanced and end-stage presentations. Guide costs for the dual-injection protocol should be confirmed with the treating clinic at the time of assessment.

For the most extreme presentations, a further escalation co-delivers autologous mesenchymal stem cells (MSCs) — sourced from bone marrow, adipose tissue, or ear cartilage — alongside both injectable products in the same session. The clinical rationale is additive: the collagen scaffold addresses the articular surface, the hydrogel the synovial compartment, and the MSCs contribute cellular signalling and repair support where the tissue condition demands more than structural coverage alone. Guide costs for this Tri-Active approach are higher, and again should be confirmed directly.

Management of a KL III–IV joint via this pathway is explicitly iterative. A structured long-term programme — incorporating bi-annual ChondroFiller top-up injections, annual MRI structural monitoring, and adjunctive peptide support — is part of the protocol design from the outset. That structure reflects the clinical reality of sustaining a significantly worn joint over years; it is managed care, not evidence of an initial treatment falling short. Keeping joint deterioration stable across the longer term is the aim, and the maintenance programme is the mechanism by which that aim is pursued.

Getting assessed for ChondroFiller at advanced OA

The starting point for any candidacy decision at KL III–IV is imaging review — specifically MRI, which characterises the pattern and extent of cartilage loss rather than simply confirming a radiographic grade. That distinction matters because, as the earlier sections make clear, the clinical question is whether residual tissue exists to anchor and recruit from, not whether the X-ray number crosses a threshold. Eligibility also requires stable joint mechanics: no untreated ligamentous instability, no significant malalignment, and no meniscal deficit driving the wear — factors the imaging review and clinical examination together establish.

A specialist with specific training in advanced cartilage and joint-preservation assessment is needed to interpret that imaging and form a view on whether scaffold integration is realistic. For patients who are suitable, ChondroFiller is delivered as an ultrasound-guided outpatient appointment — precise, image-guided placement without surgical access.

The most useful question to raise with any specialist, whether via GP referral or self-referral, is whether imaging confirms discrete residual structure or diffuse end-stage loss, and which pathway follows from that finding. Patients in London can arrange that imaging review and candidacy assessment at the London Cartilage Clinic on Harley Street; details are at londoncartilage.com.